TargetBeta
CD79B
CD79b molecule · also B29, Ig-beta, Igbeta, IGB · CD molecules
1 program in company-led studies act on CD79B, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Anti-CD79b Antibody-drug Conjugate SHR-A1912 | Jiangsu HengRui Medicine | – | phase 3 | 33 running | – | the company's pipeline |
Conditions their studies are in
- Lymphoma, B-Cell, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 2027Anti-CD79b Antibody-drug Conjugate SHR-A1912 · Jiangsu HengRui Medicine · phase 3 · NCT06929624
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.